|Molar mass||358.41 g·mol−1|
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
CERC-301 (formerly known as MK-0657) is an orally-active, selective NMDA receptor subunit 2B (NR2B) antagonist which is under development by Cerecor in the United States as an adjunctive therapy for treatment-resistant depression (TRD). In November 2013, phase II clinical trials were initiated, and in the same month, CERC-301 received Fast Track Designation from the Food and Drug Administration for TRD.
- Ibrahim L, Diaz Granados N, Jolkovsky L, et al. (August 2012). "A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder". J Clin Psychopharmacol 32 (4): 551–7. doi:10.1097/JCP.0b013e31825d70d6. PMC 3438886. PMID 22722512.
- Yahoo! Finance (2013). "Cerecor Announces Initiation of Phase 2 Study for CERC-301, an Oral Rapid-acting Antidepressant Candidate".
- Yahoo! Finance (2013). "Cerecor Receives Fast Track Designation for CERC-301 for the Treatment of Major Depressive Disorder".
- "A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment". Retrieved 2015-01-04.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|